Sex Hormones Explained — Testosterone and Estrogen

Sex hormones are among the most powerful chemical messengers in the human body. They shape bones, muscles, brains, moods, and reproduction itself. Yet they're not "male" or "female" molecules — every human body produces both testosterone and estrogen. The differences lie in the ratios, the receptors, and the timing.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

This article explains what sex hormones are, how they're made, what they do, and how the elegant feedback systems of the hypothalamic-pituitary-gonadal (HPG) axis orchestrate everything from puberty to menopause.

The Chemistry: Steroid Hormones From Cholesterol

All sex hormones are steroid hormones — small lipid molecules built from a four-ring carbon skeleton. Their starting material is surprising: cholesterol. The same molecule blamed for clogged arteries is also the raw material for every sex hormone in your body.

The biosynthesis cascade goes:

Cholesterol → Pregnenolone → Progesterone → Androgens (incl. testosterone) → Estrogens (incl. estradiol)

The enzyme aromatase is the key bridge: it converts testosterone into estradiol. This is why men have circulating estrogen too (made partly in fat tissue), and why bodybuilders who abuse androgens often develop gynecomastia — excess testosterone aromatizes into estrogen.

Because they're lipid-soluble, steroid hormones pass directly through cell membranes and bind to intracellular receptors that act as transcription factors — switching entire gene programs on or off. This is why their effects are slow to start but long-lasting.

Testosterone — Not Just a Male Hormone

Testosterone is produced primarily by the Leydig cells of the testes in males (~6–7 mg/day), with smaller amounts from the adrenal glands and ovaries in females. Normal adult male serum levels are roughly 300–1,000 ng/dL; adult females typically have 15–70 ng/dL.

What it does:

• Muscle and bone: stimulates protein synthesis, increases bone mineral density
• Hair and skin: drives facial/body hair growth, oilier skin, male-pattern baldness in genetically predisposed individuals
• Libido and mood: influences sexual desire in both sexes
• Red blood cells: stimulates erythropoiesis (one reason men have higher hematocrit)
• Brain: affects spatial cognition, aggression, and risk-taking (effects are real but modest and heavily mediated by social context)

Testosterone naturally declines with age in men — roughly 1% per year after age 30. "Andropause" is real but more gradual than menopause.

Estrogens — Three Forms, Many Roles

"Estrogen" is actually a family of three hormones:

• Estradiol (E2) — most potent, dominant in reproductive years
• Estrone (E1) — weaker, dominant after menopause
• Estriol (E3) — produced in large amounts during pregnancy by the placenta

The ovaries are the primary source in premenopausal women, with smaller contributions from the adrenals. After menopause, adipose (fat) tissue becomes the main estrogen factory via aromatase, converting adrenal androgens into estrone.

What estrogen does:

• Drives breast development and female fat distribution at puberty
• Regulates the menstrual cycle (with progesterone)
• Protects bone density (its decline at menopause is why osteoporosis risk rises sharply)
• Improves HDL/LDL cholesterol ratios (partly why premenopausal women have lower cardiovascular risk)
• Influences mood, skin elasticity, and vaginal/urinary tissue health

Progesterone — The Pregnancy Hormone

Progesterone comes mostly from the corpus luteum (the remains of the ovarian follicle after ovulation) and, during pregnancy, the placenta. Its main jobs are preparing the uterine lining for implantation, maintaining pregnancy, and suppressing further ovulation. It also raises basal body temperature — the basis of fertility-awareness tracking.

The Menstrual Cycle in Four Phases

The ~28-day menstrual cycle is a masterclass in feedback control:

1. Menstruation (days 1–5): Drop in estrogen and progesterone triggers shedding of the uterine lining.
2. Follicular phase (days 1–13): FSH from the pituitary stimulates ovarian follicles to grow; they produce rising estrogen.
3. Ovulation (~day 14): Estrogen peaks, triggering a surge of LH. The dominant follicle ruptures and releases an egg.
4. Luteal phase (days 15–28): The corpus luteum produces progesterone (and some estrogen) to prepare the endometrium. If no pregnancy, it degenerates, hormones fall, and the cycle restarts.

The HPG Axis — The Master Controller

All of this is orchestrated by the hypothalamic-pituitary-gonadal axis:

Hypothalamus → GnRH → Pituitary → LH and FSH → Gonads → Sex hormones

Sex hormones then feed back (mostly negatively) to suppress GnRH and gonadotropins, keeping the system balanced. In males the axis runs in roughly constant tonic mode, producing relatively steady testosterone. In females it cycles, producing the monthly oscillations described above.

Puberty is triggered when kisspeptin neurons in the hypothalamus mature and start pulsing GnRH release. Why this happens at age 8–14 rather than at birth is still partly mysterious — body fat, leptin, genetics, and environmental signals all play roles.

Testosterone vs Estrogen — Comparison Table

Property	Testosterone	Estradiol (Estrogen)
Class	Androgen (steroid)	Estrogen (steroid)
Main source	Testes (Leydig cells)	Ovaries (granulosa cells)
Typical adult male level	300–1,000 ng/dL	10–40 pg/mL
Typical adult female level	15–70 ng/dL	30–400 pg/mL (cycle-dependent)
Muscle effect	Strong anabolic	Modest
Bone effect	Builds bone	Protects bone (anti-resorption)
Cardiovascular	Mixed (raises hematocrit)	Generally protective premenopause
Mood/libido	Increases libido in both sexes	Improves mood in many women
Age-related decline	Gradual (~1%/yr after 30)	Sharp drop at menopause

Menopause and HRT — A Contested History

Menopause occurs (median age 51) when ovarian follicles are depleted, estrogen drops, and FSH/LH rise unchecked. Symptoms — hot flashes, sleep disruption, vaginal atrophy, bone loss, mood changes — vary enormously between individuals.

Hormone replacement therapy (HRT) was once routinely prescribed. Then the 2002 Women's Health Initiative trial reported increased risks of breast cancer, stroke, and cardiovascular events with combined estrogen + progestin therapy, and HRT use plummeted. Subsequent re-analyses showed risks depend heavily on age at initiation, type of hormones used, and route of administration. Modern guidelines support HRT for symptomatic women under 60 within 10 years of menopause, with individualized risk assessment.

Puberty and Sexual Development

Puberty represents the most dramatic shift in sex hormone levels across the lifespan. It begins with the reactivation of the HPG axis after years of quiescence in childhood. In females, pubertal hormone changes begin as early as age 8–9 (breast development, called Tanner stage 2) and continue through menarche (first menstruation, typically age 11–14) into full reproductive maturity by the late teens. In males, testicular enlargement begins around age 9–10, followed by pubic and axillary hair growth, penis enlargement, and voice deepening — all driven by rising testosterone.

Gonadarche — the reactivation of gonadal hormone production — is triggered when kisspeptin-positive neurons mature and increase their pulsatile GnRH release. Body fat, leptin, genetics, and possibly immune signals converge to set the "switch-on" age. Once initiated, the cascade is largely self-sustaining: rising gonadal steroids feed back on the hypothalamus and pituitary, but do not stop the process the way they do in adult life — puberty is a "ratchet" that only moves forward.

The effects of puberty are profound and extend far beyond reproduction. Testosterone and estrogen sculpt bone geometry (wider pelves in females, denser cortical bone in males), alter fat distribution, change skin thickness and oil production, and profoundly affect the brain. Adolescent brains show a second surge of synaptogenesis (around age 10–12) followed by selective pruning — a process that may be sensitive to sex hormone fluctuations and could underlie some of the mood, risk-taking, and social behavior changes of adolescence.

Source: Grumbach et al. (2003) in "Pediatric Endocrinology" — comprehensive review of pubertal development and hormonal mechanisms.

Hormone Receptors and Cellular Mechanisms

Sex hormones exert their effects through specific intracellular and cell-surface receptors. Estrogen receptors (ERα and ERβ) and androgen receptors (AR) are ligand-activated transcription factors — they live in the cytoplasm, bind hormone, and translocate to the nucleus where they recruit co-activators and co-repressors to modulate gene expression. This is slow (hours to days) but long-lasting.

However, sex hormones also trigger rapid, non-genomic effects via membrane-associated receptors. For example, estradiol can activate phosphatidylinositol 3-kinase (PI3K) and ERK signaling cascades within seconds, modulating neuronal firing and synaptic plasticity. This duality — slow genomic and fast non-genomic effects — explains why sex hormone impacts span from subcellular to behavioral timescales.

The distribution and expression of hormone receptors varies by tissue and cell type. Estrogen receptors are dense in:

• Hippocampus (memory)
• Amygdala (emotion, fear)
• Prefrontal cortex (executive function)
• Hypothalamus (feeding, thermoregulation, reproduction)

This receptor distribution explains why estrogen fluctuations correlate with mood, memory, sleep, and appetite changes, and why loss of estrogen at menopause can trigger cognitive symptoms and affective changes in some women.

Androgen receptors are abundant in:

• Hypothalamus and anterior pituitary (feedback control)
• Skeletal muscle (growth)
• Prostate and seminal vesicles (secondary sex organ development)
• Skin (hair, sebaceous glands)

Aging and Lifetime Hormone Changes

Sex hormone production changes predictably across the lifespan, with profound health consequences. In males, testosterone typically peaks in the late teens to early 20s (1000+ ng/dL) and declines slowly thereafter — roughly 0.5–1% per year after age 30. By age 70, a man's testosterone may be 30–50% lower than at age 25. However, this decline is gradual; the concept of "andropause" as a discrete event (analogous to female menopause) is controversial, though some men do experience mood, sexual function, or energy changes correlated with low testosterone.

In females, estrogen and progesterone remain relatively stable during the reproductive years (ages 13–51), with cyclical monthly variation. Then, beginning in the mid-40s, the perimenopause phase starts — a 5–10 year period of erratic hormone fluctuations as ovarian follicles deplete. FSH and LH rise, estrogen and progesterone swing wildly, and vasomotor symptoms (hot flashes, night sweats) become common. Then, menopause — defined as 12 consecutive months without menses — marks the end of ovarian hormone production. Estrone (from adipose aromatase) becomes the dominant circulating estrogen.

The loss of estrogen at menopause has wide-ranging effects:

• Bone: Osteoclast activity accelerates; bone mineral density drops 1–2% per year for 5–8 years postmenopause, raising osteoporosis risk sharply.
• Cardiovascular: Vasodilatory and anti-inflammatory effects of estrogen are lost. Cardiovascular disease risk rises from 1-in-50 in premenopausal women to 1-in-3 by age 65.
• Mood: Depression and anxiety become more common; mood-regulating effects of estrogen on serotonin and dopamine systems are diminished.
• Cognitive: Some women report slowed processing, attention, or word-finding during perimenopause, though longer-term effects on dementia risk remain contested.

Source: North American Menopause Society (2022) — "Management of Menopausal Symptoms" clinical consensus, 1,200+ studies reviewed.

Hormonal Contraception — Mechanisms and Tradeoffs

Oral hormonal contraceptives ("the pill") are among the most widely used medications globally, yet their mechanism is sometimes misunderstood. Modern combined estrogen–progestin pills work primarily by suppressing the LH surge that triggers ovulation. Exogenous estrogen and progestin inhibit GnRH release via negative feedback, keeping LH levels too low for the follicular rupture. Additionally, progestin thickens cervical mucus (making sperm transport harder) and alters endometrial tissue, reducing implantation risk if ovulation somehow occurs.

The hormonal doses in modern pills are far lower than in early formulations (1960s–1980s pills contained 50 μg ethinyl estradiol; today's are 20–35 μg or lower, or even estrogen-free). Lower doses mean fewer systemic effects but also stricter pill-taking discipline needed for efficacy — missing even a single day during the follicular phase can allow ovulation.

Progestin-only methods ("the minipill") work primarily via cervical mucus thickening and endometrial atrophy; they do not reliably suppress ovulation, making them slightly less effective than combined pills but often preferred in lactating women (estrogen can reduce milk production) and women over 35 with cardiovascular risk factors.

Long-acting reversible contraception (LARC) — intrauterine devices (IUDs) and subdermal implants — work via local delivery of levonorgestrel (progestin) or by copper-induced inflammation; ovulation suppression is partial or absent (except for the hormonal IUD), yet efficacy is 99%+. These methods eliminate compliance issues and are increasingly first-line for long-term contraception.

Gender-Affirming Hormone Therapy

Gender-affirming hormone therapy (GAHT) uses sex hormones to align secondary sex characteristics with gender identity. For transmasculine individuals (assigned female at birth, male gender identity), testosterone therapy increases muscle, deepens voice, coarsens skin, and redistributes fat. For transfeminine individuals, estrogen + anti-androgens (spironolactone, cyproterone acetate, or 5α-reductase inhibitors) achieve female fat distribution, breast growth, and muscle loss.

The timeline of GAHT changes is clinically significant. Testosterone effects in transmasculine individuals develop over months to years:

• Menses cessation: 1–3 months
• Voice deepening: 3–6 months
• Clitoral growth: 1–6 months
• Muscle/fat redistribution: 3–12 months
• Facial/body hair growth: 3–12 months (facial hair may take 2+ years)

Estrogen + anti-androgen therapy in transfeminine individuals:

• Erections become rare: 1–3 months
• Breast growth (budding): 1–3 months, continued growth for 2–5 years
• Fat redistribution: 3–6 months, progressive over 2–5 years
• Facial/body hair slows but does not reverse (laser/electrolysis needed)
• Voice does not change (speech therapy or surgery needed)

Importantly, some changes are irreversible or slow to reverse. If testosterone therapy is stopped, clitoral enlargement and most facial/body hair persist; if estrogen is discontinued, voice and facial hair changes in transfeminine individuals do not reverse. This irreversibility underscores the importance of informed consent and careful psychiatric evaluation before initiating GAHT, especially in adolescents.

Source: Endocrine Society (2009) — "Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline," J Clin Endocrinol Metab, 94(9):3132–3154.

Hormone Testing and Measurement

Sex hormone levels are typically measured via serum assays. For testosterone, a fasting morning draw is standard (testosterone shows diurnal variation, highest in early morning). For estradiol and progesterone, cycle phase matters: luteal-phase progesterone (day 21 of a 28-day cycle) is most informative. FSH and LH help distinguish primary hypogonadism (high FSH/LH, low sex hormone) from secondary (low FSH/LH, low sex hormone).

Reference ranges vary by age, sex, and cycle phase. For adult males, testosterone is 300–1,000 ng/dL (10–35 nmol/L SI units). For adult females, cycle-dependent ranges for estradiol are 30–100 pg/mL (follicular phase) to 100–400 pg/mL (peak estrogen surge). Progesterone in the luteal phase is typically 5–20 ng/mL (16–64 nmol/L).

Bioavailable testosterone (the fraction not bound to sex hormone-binding globulin, SHBG) is sometimes more clinically relevant than total testosterone, especially in men with elevated SHBG (aging, hyperthyroidism, liver disease, estrogen therapy). Testosterone-binding globulin itself is regulated by estrogen (raising SHBG) and insulin (lowering SHBG), adding another layer of physiological complexity.

Immunoassays (ELISA, radioimmunoassay) are the standard, but LC-MS/MS (liquid chromatography-tandem mass spectrometry) is more specific and increasingly used, especially for low estradiol levels in postmenopausal women or men.

Other Hormone Therapies and Emerging Treatments

• Testosterone replacement therapy (TRT) for men with clinically low levels (hypogonadism defined as total testosterone <300 ng/dL with symptoms) can improve libido, muscle, bone density, and mood. However, TRT is controversial for age-related decline (andropause) without overt hypogonadism; risks include polycythemia (elevated red blood cells), prostate aggravation, and cardiovascular effects (still debated). Current guidelines recommend assessing symptom benefit vs. individual risk.

• Anti-estrogens (tamoxifen for breast cancer; aromatase inhibitors like letrozole for postmenopausal ER+ tumors) block estrogen action or production. These are life-saving in hormone-sensitive cancers but cause menopausal symptoms and bone loss in premenopausal and postmenopausal women.

• Selective estrogen receptor modulators (SERMs) like raloxifene act as estrogen agonists in bone (preventing osteoporosis) and antagonists in breast — trying to capture estrogen's benefits while avoiding cancer risk. SERMs show promise in fracture prevention but have not yet rivaled HRT for symptom relief.

• DHEA supplementation is popular but evidence is weak. DHEA levels decline with age, but supplementation does not consistently raise testosterone or estrogen or improve sexual function in trials.

Hormonal and non-hormonal therapies depend on understanding the broader endocrine network. These systems interconnect at every level: the hypothalamus receives metabolic and emotional signals, the pituitary orchestrates multiple hormone axes, and peripheral tissues integrate hormonal and neural input.

---

What This Means

Sex hormones orchestrate reproduction, body composition, mood, and health across the lifespan. Both testosterone and estrogen are essential in both sexes; the ratios and timing determine phenotype and function. Understanding these hormones informs everything from puberty and fertility to menopause and therapy choices — biology's most elegant feedback system.

---

Frequently Asked Questions

Q: Do men and women produce the same hormones?
A: Yes—both produce testosterone, estrogen, and progesterone. The ratios and absolute amounts differ dramatically, but the molecules are identical. A typical woman's testosterone is 1/10th of a man's, but both rely on all three hormones for health.

Q: Does testosterone make people more aggressive?
A: The effect is real but modest. Meta-analyses show small correlations with aggression and risk-taking, heavily mediated by context, expectations, and social factors. Testosterone amplifies existing behavioral tendencies rather than creating them de novo.

Q: Is hormone replacement therapy (HRT) safe?
A: For most healthy women under 60 within 10 years of menopause, benefits outweigh risks for symptom relief. Risks rise with age and certain conditions (prior breast cancer, clotting disorder). It's a personalized decision between patient and physician based on individual risk profile.

Q: Why do some men develop breast tissue on anabolic steroids?
A: Excess testosterone is converted to estrogen by the aromatase enzyme, especially in fat tissue. High circulating estrogen stimulates breast tissue growth (gynecomastia) in males, a side effect that's reversible if hormone use stops.

Q: Does eating soy increase estrogen and feminize males?
A: Soy contains phytoestrogens (isoflavones) that weakly bind human estrogen receptors. At normal dietary levels, effects on circulating hormone levels are minimal. Large meta-analyses show no harm to males at typical soy consumption; this is a persistent myth without strong evidence.

Q: How do sex hormones affect memory and mood?
A: Estrogen receptors are abundant in the hippocampus (memory) and amygdala (emotion). Hormone fluctuations correlate with mood and memory changes, which is why some women experience cognitive symptoms during perimenopause or certain phases of the menstrual cycle.

---

Read next:

• How Hormones Control Your Body
• Dopamine System Explained: Reward and Motivation
• How Memory Works in the Brain